Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sage Therapeutics : Cowen Adjusts Sage Therapeutics' Price Target to $105 from $100, Keeps Outperform Rating

06/16/2021 | 10:26am EDT


ę MT Newswires 2021
All news about SAGE THERAPEUTICS, INC.
07/27SAGE THERAPEUTICS : Canaccord Genuity Adjusts Price Target on Sage Therapeutics ..
MT
07/23DGAP-NEWS : Il settore delle biotecnologie -2-
DJ
07/23PRESS RELEASE : Solid second quarter for the -2-
DJ
07/20SAGE THERAPEUTICS : to Report Second Quarter 2021 Financial Results on Tuesday, ..
BU
07/09SAGE THERAPEUTICS : to Participate in Cowen's Psychedelics & Novel Mechanisms in..
AQ
07/08SAGE THERAPEUTICS : to Participate in Cowen's Psychedelics & Novel Mechanisms in..
BU
06/28SAGE THERAPEUTICS' : Price Target From RBC Cut to $60 From $84; Survey Suggests ..
MT
06/28BIOGEN : Price Target From RBC Cut to $354 From $400 Amid Adjusted Estimates for..
MT
06/25SAGE THERAPEUTICS : to Participate in SVB Leerink's 3rd Annual CNS Forum
AQ
06/25SAGE THERAPEUTICS, INC.(NASDAQGM : SAGE) dropped from Russell 3000E Growth Index
CI
More news
Financials (USD)
Sales 2021 9,14 M - -
Net income 2021 -413 M - -
Net cash 2021 1 499 M - -
P/E ratio 2021 -6,38x
Yield 2021 -
Capitalization 2 611 M 2 611 M -
EV / Sales 2021 122x
EV / Sales 2022 10,0x
Nbr of Employees 298
Free-Float 87,6%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 44,65 $
Average target price 87,53 $
Spread / Average Target 96,0%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer & Treasurer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
James Doherty Chief Research Officer
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.-48.39%2 611
GILEAD SCIENCES, INC.20.25%87 868
BIONTECH SE284.51%75 705
WUXI APPTEC CO., LTD.36.10%68 994
REGENERON PHARMACEUTICALS21.38%60 726
VERTEX PHARMACEUTICALS-14.43%52 353